picibanil and Adenoma

A human monoclonal antibody, YJ-37 (IgM) was generated through the fusion of human B lymphoblastoid cell line HO-323 with the regional lymph node lymphocytes from a colonic cancer patient who was treated with a local immunotherapy. This antibody was purified and conjugated with biotin, after which direct immunohistochemical staining was performed. The results revealed that YJ-37 selectively reacted with colonic cancer (7/19), gastric cancer (3/6), endometrial cancer (1/2) and colonic adenoma (7/13), but not with normal epithelia. Membrane immunofluorescence and FACS analysis also showed that YJ-37 bound to tumor cell surfaces. Furthermore, the chemical structure of the antigen defined by YJ-37 was analyzed by means of thin-layer chromatography immunostaining and ELISA. The results indicated that YJ-37 reacted with sialylated lacto-series carbohydrate chains, which have been reported to accumulate in cancer cells.

Topics: Adenoma; Antibodies, Monoclonal; B-Lymphocytes; Carbohydrate Conformation; Carbohydrate Sequence; Cell Fusion; Cell Line; Colonic Neoplasms; Endometrial Neoplasms; Enzyme-Linked Immunosorbent Assay; Female; Fibrinogen; Glycolipids; Humans; Immunotherapy; Lymph Nodes; Lymphocytes; Molecular Sequence Data; Picibanil; Stomach Neoplasms

Topics: Abortion, Therapeutic; Adenocarcinoma, Mucinous; Adenoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Humans; Middle Aged; Ovarian Neoplasms; Ovariectomy; Peptichemio; Picibanil; Pregnancy; Pregnancy Complications, Neoplastic; Prognosis

Topics: Adenoma; Adjuvants, Immunologic; Biological Products; Carcinoma, Squamous Cell; Humans; Lung Neoplasms; Picibanil; Proteoglycans